1. Holly
Whitten
Scott
Raleigh.
NC
|
c:
919.880.6089
|
hollywscott@gmail.com
SUMMARY
Seasoned
pharmaceutic
product
marketing
and
sales
professional
with
over
15
years
of
experience
in
the
U.S.
and
Globally
for
in-­‐line
and
developmental
drugs
and
medical
devices.
EXPERIENCE
THE
LUCIGHT
GROUP,
LLC.
|
Raleigh
.
NC
5.2015
-­‐
Present
Founder
&
Consultant
§ Provide
brand
planning
to
small
to
medium
size
businesses
across
numerous
verticals
SALIX
PHARMACEUTICALS,
INC.
|
Raleigh
.
NC
5.2012
-­‐
4.2015
Senior
Product
Manager,
RUCONEST
(2.2014
-­‐
4.2015)
§ Mobilized
internal
and
external
stakeholders
for
launch
of
RUCONEST;
Completed
launch
plan
research,
development,
and
execution
in
8
months
with
limited
budget
and
sales
are
currently
trending
to
exceed
goal
§ Built
and
managed
HAEA
and
HAEi
ultra-­‐orphan
disease
patient
advocacy
group
relationships,
meeting
bi-­‐weekly
with
senior
leadership
team,
leading
to
the
President
and
KOL
speaking
at
RUCONEST
launch
§ Launched
innovative
contest
introducing
Salix
to
the
HAE
community
and
building
database
of
over
300
patients;
Exceeded
database
goal
by
500%
§ Developed
and
grew
relationships
with
U.S.
HAE
“Center
of
Excellence”
KOLs,
Dr.
Marc
Riedl
and
Dr.
Bruce
Zuraw;
Resulted
in
securing
physician
press
release
quotes,
fielding
media
calls,
and
participation
in
Satellite
Media
Tour
§ Coordinated
with
manage
markets
team
and
director
of
reimbursement
to
establish
RUCONEST
specialty
pharmacies
and
patient
services
hub
including:
reimbursement
and
financial
assistance,
nursing
care,
and
product
training
§ Collaborated
with
Regulatory,
Medical
Affairs,
and
Clinical
Development
teams
to
support
launch
and
strategic
goals
§ Built
and
rolled
out
sales
rep
training
initiatives,
patient/caregivers
self-­‐administration
training,
and
nurse
training/certification
programs
§ As
the
company’s
recognized
orphan
disease
expert,
spearheaded
1st
companywide
education
on
unique
commercial
intricacies
of
launching
RUCONEST
§ Completed
market
assessments
to
determine
whether
to
pursue
RUCONEST
for
hereditary
angioedema
or
additional
indications;
Presented
recommendations
to
senior
leadership;
Recognized
as
1
of
4
Salix
cornerstone
programs
§ Managed
multiple
market
research
projects
in
preparation
for
launch
including:
physician
positioning,
concept
and
message
testing,
competitive
analysis,
and
quantitative
patient
segmentation
Senior
Product
Manager,
Solesta
(5.2012
-­‐
2.2014)
§ Established
strategy
and
executed
tactical
HCP
plan
to
increase
the
number
of
injecting
accounts
for
Salix’s
1st
medical
device,
an
injectable
implant
for
fecal
incontinence;
Resulted
in
522
procedures
in
2012
and
1,916
in
2013
(267%)
§ Managed
market
research
to
determine
the
value
proposition
for
Solesta;
Incorporated
learning
into
a
value-­‐based
selling
education
and
training
program
for
the
sales
team;
Resulted
in
accelerated
product
adoption
§ Developed
and
rolled
out
national
“best-­‐in-­‐class”
physician
training
program
§ Created
and
rolled
out
on-­‐demand
physician
training
program
empowering
sales
team
to
train
physicians
directly;
Resulted
in
rep
credibility
and
individual
training
cost
reduction
for
636
physicians
from
$3750
to
$200
in
year
1
and
$130
in
subsequent
years;
saving
the
company
$2.25M
in
training
costs
in
2014
§ Developed
and
implemented
sales
process
tool
to
sell
in
“buy
and
bill”
environment,
improved
territory
efficiencies
and
effectiveness
GRIFOLS,
INC.
(formerly
Talecris
Biotherapeutics
&
Bayer
Biological
Products)
|
RTP
.
NC
6.2004
-­‐
4.2012
Associate
Director,
Global
Commercial
Development
Pulmonary
&
Hematology
(10.2007
-­‐
4.2012)
§ Led
commercial
product
life-­‐cycle
management,
new
product
planning,
and
development
and
maintenance
of
business
cases
and
financial
analysis
for
pipeline
products
and
new
indications
§ Managed
global
brand
alignment
and
efficiencies
across
US,
Canada,
and
Europe

2. § Led
launch
team,
including
11
subteams,
in
the
U.S.
and
Canada
in
the
development
of
commercialization
strategy
and
business
case
for
Prolastin-­‐C
Liquid
in
late-­‐stage
development
for
alpha-­‐1
antitrypsin
deficiency
§ Commercial
lead
for
Plasmin,
a
thrombolytic
in
mid-­‐stage
development
§ Member
of
US
launch
team
for
Prolastin-­‐C;
managed
translation
of
clinical
data
to
messages
and
materials
for
global
markets
including:
comprehensive
monograph,
training
materials,
scientific
slide
decks,
and
press
releases
§ Managed
KOL
Advisory
Boards
gaining
insight
on
various
aspects
of
brand
globally
for
Pulmonary
franchise
§ Developed
and
managed
global
communication
plan
and
global
health
economics
and
outcomes
research
strategy
§ Served
on
two
global
project
teams
as
primary
commercial
partner
to
research
and
development
Senior
Product
Manager/Product
Manager,
Hematology
(6.2005
-­‐
9.2007)
§ Relaunched
Thrombate
III
for
hereditary
antithrombin
deficiency
in
U.S.
market,
managed
global
commercial
development
plan,
and
conducted
market
assessments
for
new
indications
§ Delivered
business
case
reversing
decision
to
discontinue
production
and
exit
the
market;
Resulted
in
920%
increase
in
annual
company
spend
and
major
manufacturing
project
approval
involving
high
capital
expenditures
§ Achieved
sales
growth
of
over
31%
in
2007
(volume
growth
=
17%)
and
36%
in
2006
(volume
growth
=34%),
without
sales
force
support
§ Secured
partners,
built,
and
led
a
cross-­‐functional
team
driving
all
initiatives
around
Thrombate
III
including
clinical
development,
scientific
communications,
CME
activity,
KOL
development,
and
promotions
§ Identified,
developed,
and
maintained
national
KOL
relationships:
resulted
in
multiple
clinical
initiatives
§ Built
relationships
with
key
distributors
and
GPO
partners
elevating
Thrombate
III
brand
and
driving
sales
§ Partnered
with
patient
advocacy
group
(NATT)
on
development,
printing,
and
distribution
of
treatment
guidelines
§ Served
on
global
project
team
as
primary
commercial
partner
to
research
and
development
Market
Research
Analyst
(6.2004
-­‐
6.2005)
§ Conducted
primary
and
secondary
research,
analyzed
and
reported
results,
and
made
recommendations
about
strategic
direction
for
specific
product
lines
NABI|
Boca
Raton
.
FL
12.2000
-­‐
1.2002
Product
Specialist,
Territory
NC
&
VA
§ Ranked
#1
regionally
out
of
8
and
#2
nationally
out
of
43
in
sales
and
company
growth
§ Sold
4
biotechnology
plasma-­‐based
prescription
drugs
WinRho
SDF
(ITP),
Autoplex
T
(Hemophilia),
Aloprim
(Oncology),
and
Nabi
HB
(Hepatitis
B)
to
Pediatric
and
Adult
Hem/Onc
Physicians,
Hepatologists/Liver
Transplant
JANSSEN
PHARMACEUTICA
|
Titusville
.
NJ
2.1999
-­‐
12.2000
Sales
Representative,
Territory
Greensboro
.
NC
§ Ranked
#3
in
district
out
of
8,
,
#15
regionally
out
of
45,
and
#72
nationally
out
of
275
in
sales
and
company
growth;
Awarded
2
times
the
District
Representative
of
the
Quarter
§ Sold
4
prescription
drugs
(Duragesic,
Aciphex,
Sporonox,
and
Propulsid)
to
high
prescribing
Primary
Care
Physicians,
Neurologists,
Anesthesiologists,
Rheumatologists,
Physiatrists,
Dermatologists,
and
Podiatrists
ALLIANT
FOODSERVICE,
INC.
|
Charlotte
.
NC
3.1998
-­‐
2.1999
Territory
Manager,
Territory
Columbia
.
SC
§ Increased
sales
in
new
and
existing
accounts
by
50%
in
assigned
territory;
Achieved
highest
district
sales
EDUCATION
EAST
CAROLINA
UNIVERSITY
5.2005
Master
of
Business
Administration:
Healthcare
Management
Certificate
GPA:
3.9
&
member
of
Sigma
Iota
Epsilon
-­‐
National
and
Professional
Management
Honorary
Fraternity
UNIVERSITY
OF
NORTH
CAROLINA
AT
GREENSBORO
12.1997
Bachelor
of
Science
in
Management/Marketing:
Concentration
Marketing